Passivity-Based Inverse Optimal Impulsive Control for Influenza Treatment in the Host
暂无分享,去创建一个
Alma Y. Alanis | Rolf Findeisen | Esteban A. Hernandez-Vargas | Gustavo Hernandez-Mejia | Miguel Hernandez-Gonzalez | R. Findeisen | A. Alanis | E. Hernández-Vargas | M. Hernández-González | Gustavo Hernandez-Mejia
[1] F. Hayden,et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. , 1996, JAMA.
[2] N. J. White,et al. Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers , 2008, Antimicrobial Agents and Chemotherapy.
[3] Florian Krammer,et al. Influenza virus hemagglutinin stalk-based antibodies and vaccines. , 2013, Current opinion in virology.
[4] V. Georgiev,et al. National Institute of Allergy and Infectious Diseases, NI , 2008 .
[5] Isaac I. Bogoch,et al. Have you herd? Indirect flu vaccine effects are critically important. , 2017, The Lancet. Public health.
[6] Ryan Zurakowski,et al. Nonlinear observer output-feedback MPC treatment scheduling for HIV , 2011, Biomedical engineering online.
[7] Alma Y. Alanis,et al. Inverse Optimal Impulsive Control Based Treatment of Influenza Infection , 2017 .
[8] L. Jakubcová,et al. Comparison of infectious influenza A virus quantification methods employing immuno-staining. , 2017, Journal of virological methods.
[9] Donald E. Kirk,et al. Optimal control theory : an introduction , 1970 .
[10] Van Kinh Nguyen,et al. Windows of opportunity for Ebola virus infection treatment and vaccination , 2017, bioRxiv.
[11] D. M. Ryan,et al. Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.
[12] Alma Y. Alanis,et al. Recurrent High Order Neural Networks Identification for Infectious Diseases , 2018, 2018 International Joint Conference on Neural Networks (IJCNN).
[13] Satoshi Fukuyama,et al. The pathogenesis of influenza virus infections: the contributions of virus and host factors. , 2011, Current opinion in immunology.
[14] D. Normand-Cyrot,et al. Control Lyapunov stabilization of affine discrete-time systems , 1997, Proceedings of the 36th IEEE Conference on Decision and Control.
[15] Laurent Kaiser,et al. Influenza virus neuraminidase inhibitors , 2000, The Lancet.
[16] Alma Y. Alanis,et al. Impulsive MPC for Influenza Infection Treatment at Variable Time , 2018 .
[17] E. D. Kilbourne. Influenza Pandemics of the 20th Century , 2006, Emerging infectious diseases.
[18] C. Abdallah,et al. Optimal discrete-time control for non-linear cascade systems , 1998 .
[19] Katherine L. Milkman,et al. Using implementation intentions prompts to enhance influenza vaccination rates , 2011, Proceedings of the National Academy of Sciences.
[20] E. Sánchez,et al. Inverse optimal control for discrete‐time nonlinear systems via passivation , 2014 .
[21] B. Davies,et al. Pharmacokinetics of oseltamivir: an oral antiviral for the treatment and prophylaxis of influenza in diverse populations , 2010, The Journal of antimicrobial chemotherapy.
[22] Andreas Handel,et al. Neuraminidase Inhibitor Resistance in Influenza: Assessing the Danger of Its Generation and Spread , 2007, PLoS Comput. Biol..
[23] Alma Y. Alanis,et al. Neural inverse optimal control for discrete-time impulsive systems , 2018, Neurocomputing.
[24] Xiaohua Xia,et al. Mathematical Modeling of HIV Dynamics After Antiretroviral Therapy Initiation: A Review , 2014, BioResearch open access.
[25] Vlado Dančík,et al. A Structural and Mathematical Modeling Analysis of the Likelihood of Antibody-Dependent Enhancement in Influenza. , 2016, Trends in microbiology.
[26] Ronald Gieschke,et al. Population Pharmacokinetics of Oseltamivir When Coadministered With Probenecid , 2008, Journal of clinical pharmacology.
[27] Tao Yang,et al. Impulsive control , 1999, IEEE Trans. Autom. Control..
[28] Yu-Ann Fang,et al. Influenza Vaccination is Associated with Lower Risk of Acute Coronary Syndrome in Elderly Patients with Chronic Kidney Disease , 2016, Medicine.
[29] P. Ward,et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. , 1999, JAMA.
[30] Andreas Handel,et al. Towards a quantitative understanding of the within-host dynamics of influenza A infections , 2010, Journal of The Royal Society Interface.
[31] Jennifer L. Reed,et al. Severe Human Lower Respiratory Tract Illness Caused by Respiratory Syncytial Virus and Influenza Virus Is Characterized by the Absence of Pulmonary Cytotoxic Lymphocyte Responses , 2007, The Journal of infectious diseases.
[32] S. Hensley,et al. Challenges of selecting seasonal influenza vaccine strains for humans with diverse pre-exposure histories. , 2014, Current opinion in virology.
[33] Alan S. Perelson,et al. Quantifying the Early Immune Response and Adaptive Immune Response Kinetics in Mice Infected with Influenza A Virus , 2010, Journal of Virology.
[34] D. Cummings,et al. Strategies for mitigating an influenza pandemic , 2006, Nature.
[35] Takeshi Kurata,et al. Defense mechanisms against influenza virus infection in the respiratory tract mucosa. , 2004, Japanese journal of infectious diseases.
[36] A. Perelson,et al. Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.
[37] R.A. Freeman,et al. Optimal nonlinear controllers for feedback linearizable systems , 1995, Proceedings of 1995 American Control Conference - ACC'95.
[38] Esteban A. Hernandez-Vargas,et al. Oseltamivir PK/PD Modeling and Simulation to Evaluate Treatment Strategies against Influenza-Pneumococcus Coinfection , 2016, Front. Cell. Infect. Microbiol..
[39] Isaac Chairez Oria,et al. Nonlinear discrete time neural network observer , 2013, Neurocomputing.
[40] B. Anderson,et al. Optimal control: linear quadratic methods , 1990 .
[41] Nicholas J. White,et al. Oseltamivir Is Adequately Absorbed Following Nasogastric Administration to Adult Patients with Severe H5N1 Influenza , 2008, PloS one.
[42] Michael Meyer-Hermann,et al. PK/PD-based adaptive tailoring of oseltamivir doses to treat within-host influenza viral infections. , 2018, Progress in biophysics and molecular biology.
[43] Alan S. Perelson,et al. Impact of Different Oseltamivir Regimens on Treating Influenza A Virus Infection and Resistance Emergence: Insights from a Modelling Study , 2014, PLoS Comput. Biol..
[44] Michael Meyer-Hermann,et al. Modeling Influenza Virus Infection: A Roadmap for Influenza Research , 2015, Viruses.
[45] Richard H. Middleton,et al. Computer simulation of structured treatment interruption for HIV infection , 2011, Comput. Methods Programs Biomed..
[46] L. Fabrigar,et al. Using behavior change frameworks to improve healthcare worker influenza vaccination rates: A systematic review. , 2016, Vaccine.
[47] Pyung Hun Chang,et al. Time Delay Observer: A Robust Observer for Nonlinear Plants , 1997 .
[48] Alma Y. Alanis,et al. Observers for biological systems , 2014, Appl. Soft Comput..
[49] Nathorn Chaiyakunapruk,et al. Interdisciplinary pharmacometrics linking oseltamivir pharmacology, influenza epidemiology and health economics to inform antiviral use in pandemics , 2017, British journal of clinical pharmacology.
[50] John Samuel,et al. A simple cellular automaton model for influenza A viral infections. , 2004, Journal of theoretical biology.